3-({[BIS-(2-ETHOXY-ETHOXY)-PHOSPHORYL]-PHENYL-METHYL}-AMINO)-2-CYANO-3-METHYLSULFANYL-ACRYLIC ACID METHYL ESTER


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FAGWOTLXNMKDDC-CZIZESTLSA-N
Smiles	CCOCCOP(=O)(OCCOCC)C(N\C(=C(\C#N)/C(=O)OC)\SC)c1ccccc1
InChI	InChI=1S/C21H31N2O7PS/c1-5-27-12-14-29-31(25,30-15-13-28-6-2)19(17-10-8-7-9-11-17)23-20(32-4)18(16-22)21(24)26-3/h7-11,19,23H,5-6,12-15H2,1-4H3/b20-18+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H31N2O7PS
Molecular Weight	486.52
AlogP	2.24
Hydrogen Bond Acceptor	10.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	17.0
Polar Surface Area	151.21
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	32.0

Assay Description	Organism	Bioactivity
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected left side of tobacco leaves assessed as inactivation effect by decreasing local lesion number at 500 mg/l co-incubated with virus for 30 min before inoculation onto leaves measured at 3-4 days after viral challenge	Tobacco mosaic virus	0.0 %
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected left side of tobacco leaves assessed as curative effect by decreasing local lesion number at 500 mg/l treated after viral inoculation measured at 3-4 days after viral challenge	Tobacco mosaic virus	4.3 %
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected left side of tobacco leaves assessed as protective effect by decreasing local lesion number at 500 mg/l treated 12 hr before viral inoculation measured at 3-4 days after viral challenge	Tobacco mosaic virus	0.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2227720
PubChem	45277304

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).